NuPathe receives FDA approval for acute treatment of migraine
NuPathe Inc., a pharmaceutical company, has received the FDA approval for Zecuity, or sumatriptan iontophoretic transdermal system, for the acute treatment of migraine with or without aura in adults.
MAP0004, a novel orally inhaled formulation of dihydroergotamine currently under development, may be effective in treating a broad spectrum of migraine, according to 2 phase 3 studies presented here September 12 at the 14th Congress of the International Headache Society & the 51st Annual Scientific Meeting of the American Headache Society.